Should I buy or sell Swedish Orphan Biovitrum AB (publ) stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Swedish Orphan Biovitrum AB (publ) in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BIOVF shares. View BIOVF analyst ratings or view top-rated stocks .

How have BIOVF shares performed in 2024?

Swedish Orphan Biovitrum AB (publ)'s stock was trading at $26.25 at the beginning of the year. Since then, BIOVF stock has decreased by 12.9% and is now trading at $22.87. View the best growth stocks for 2024 here .

Are investors shorting Swedish Orphan Biovitrum AB (publ)?

Swedish Orphan Biovitrum AB (publ) saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 734,400 shares, an increase of 9.8% from the March 15th total of 669,100 shares. Based on an average trading volume of 200 shares, the short-interest ratio is currently 3,672.0 days. View Swedish Orphan Biovitrum AB (publ)'s Short Interest .

How were Swedish Orphan Biovitrum AB (publ)'s earnings last quarter?

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) announced its quarterly earnings results on Thursday, February, 8th. The company reported $0.30 EPS for the quarter, missing the consensus estimate of $0.56 by $0.26. The company earned $643.39 million during the quarter, compared to analyst estimates of $668.74 million. Swedish Orphan Biovitrum AB (publ) had a net margin of 10.95% and a trailing twelve-month return on equity of 8.93%.

How do I buy shares of Swedish Orphan Biovitrum AB (publ)?

Shares of BIOVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:BIOVF

Swedish Orphan Biovitrum AB (publ) (BIOVF) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free BIOVF Stock Alerts

$22.87

-2.13 (-8.52%)

(As of 04/18/2024 ET)

Compare

Today's Range: $22.87
▼
$23.74
50-Day Range: $22.87
▼
$27.79
52-Week Range: $18.35
▼
$27.79

Volume: 3,000 shs
Average Volume: 47 shs
Market Capitalization: N/A

P/E Ratio: 31.76
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Earnings Headlines Short Interest

Get Swedish Orphan Biovitrum AB (publ) alerts:

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Swedish Orphan Biovitrum AB (publ) Stock (OTCMKTS:BIOVF)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to treat paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

BIOVF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BIOVF Stock News Headlines

April 17, 2024 | americanbankingnews.com

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Short Interest Update

April 4, 2024 | prnewswire.com

Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 2, 2024 | finance.yahoo.com

Sobi publishes Annual and sustainability report for 2023

February 20, 2024 | au.finance.yahoo.com

Swedish Orphan Biovitrum AB (publ) (SWOBY)

February 8, 2024 | finance.yahoo.com

Sobi publishes Q4 2023 report: Strong revenue performance and growth into 2024

February 3, 2024 | realmoney.thestreet.com

Swedish Orphan Biovitrum price target raised to SEK 385 at RBC Capital

February 1, 2024 | finance.yahoo.com

All You Need to Know About Swedish Orphan Biovitrum (BIOVF) Rating Upgrade to Strong Buy

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

January 24, 2024 | finance.yahoo.com

Invitation: Sobi's Q4 and FY 2023 report

January 5, 2024 | finance.yahoo.com

Sobi's Chairman of the Board resigns due to health reasons

November 30, 2023 | finance.yahoo.com

Change in number of shares and votes in Swedish Orphan Biovitrum AB (publ)

November 23, 2023 | morningstar.com

Swedish Orphan Biovitrum AB BIOVF

November 1, 2023 | finance.yahoo.com

Sobi has completed the issuances of series C shares

October 30, 2023 | msn.com

Swedish Orphan Biovitrum AB Non-GAAP EPS of SEK0.54, revenue of SEK5.17B

October 30, 2023 | finance.yahoo.com

Swedish Orphan Biovitrum (BIOVF) Q3 Earnings Miss Estimates

October 30, 2023 | finance.yahoo.com

Sobi publishes Q3 2023 report: Strong revenue and solid performance

October 27, 2023 | finance.yahoo.com

Reminder: Invitation: Sobi's Q3 2023 report

October 18, 2023 | finance.yahoo.com

Invitation: Sobi's Q3 2023 report

September 15, 2023 | finance.yahoo.com

Reminder: Sobi KOL investor event: Advancing the standard of care in haemophilia

September 8, 2023 | finance.yahoo.com

Sobi KOL investor event: Advancing the standard of care in haemophilia

August 29, 2023 | finance.yahoo.com

Is Swedish Orphan Biovitrum (BIOVF) Stock Undervalued Right Now?

August 22, 2023 | finance.yahoo.com

Sobi resolves on a rights issue of approximately SEK 6,024 million

August 15, 2023 | finance.yahoo.com

Bulletin from Swedish Orphan Biovitrum (Sobi)'s Extraordinary General Meeting (EGM)

July 19, 2023 | tmcnet.com

Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)

July 18, 2023 | finance.yahoo.com

Swedish Orphan Biovitrum (BIOVF) Beats Q2 Earnings and Revenue Estimates

July 18, 2023 | prnewswire.com

Sobi publishes Q2 2023 report: Growth and pipeline expansion

See More Headlines

Receive BIOVF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Swedish Orphan Biovitrum AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/08/2024
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: N/A
Sub-Industry: N/A
Current Symbol: OTCMKTS:BIOVF
CUSIP: N/A
CIK: N/A
Web: www.sobi.com
Phone: (468) 697-2000
Fax: N/A
Employees: 1,612
Year Founded: 2001

Profitability

EPS (Most Recent Fiscal Year): $0.72
Trailing P/E Ratio: 31.76
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $227.17 million
Net Margins: 10.95%
Pretax Margin: 13.35%
Return on Equity: 8.93%
Return on Assets: 3.98%

Debt

Debt-to-Equity Ratio: 0.34
Current Ratio: 0.66
Quick Ratio: 0.46

Sales & Book Value

Annual Sales: $2.09 billion
Price / Sales: N/A
Cash Flow: $1.74 per share
Price / Cash Flow: 13.13
Book Value: $10.82 per share
Price / Book: 2.11

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 0.49

Social Links

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Dr. Guido Oelkers (Age 59)
CEO & President
Comp: $22.78M
Mr. Henrik Stenqvist (Age 57)
Chief Financial Officer
Mr. Torbjörn Hallberg (Age 55)
General Counsel & Head of Legal Affairs
Mr. Daniel Rankin (Age 44)
Head of Strategy & Corporate Development
Ms. Lena Bjurner (Age 56)
Head of Human Resources
Mr. Armin Reininger M.D. (Age 67)
Ph.D., Senior Scientific & Medical Advisor
Mr. Norbert Oppitz (Age 57)
Head of International
Mr. Sofiane Fahmy (Age 52)
Head of Europe
Mr. Duane H. Barnes (Age 64)
Head of North America
Mr. Mahmood Ladha (Age 60)
Head of Strategic Transformation Operations

Key Competitors

View All Competitors

BIOVF Stock Analysis - Frequently Asked Questions

Should I buy or sell Swedish Orphan Biovitrum AB (publ) stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Swedish Orphan Biovitrum AB (publ) in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BIOVF shares.
View BIOVF analyst ratings or view top-rated stocks.
How have BIOVF shares performed in 2024?: Swedish Orphan Biovitrum AB (publ)'s stock was trading at $26.25 at the beginning of the year. Since then, BIOVF stock has decreased by 12.9% and is now trading at $22.87.
View the best growth stocks for 2024 here.
Are investors shorting Swedish Orphan Biovitrum AB (publ)?: Swedish Orphan Biovitrum AB (publ) saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 734,400 shares, an increase of 9.8% from the March 15th total of 669,100 shares. Based on an average trading volume of 200 shares, the short-interest ratio is currently 3,672.0 days.
View Swedish Orphan Biovitrum AB (publ)'s Short Interest.

How were Swedish Orphan Biovitrum AB (publ)'s earnings last quarter?: Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) announced its quarterly earnings results on Thursday, February, 8th. The company reported $0.30 EPS for the quarter, missing the consensus estimate of $0.56 by $0.26. The company earned $643.39 million during the quarter, compared to analyst estimates of $668.74 million. Swedish Orphan Biovitrum AB (publ) had a net margin of 10.95% and a trailing twelve-month return on equity of 8.93%.
How do I buy shares of Swedish Orphan Biovitrum AB (publ)?: Shares of BIOVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:BIOVF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Swedish Orphan Biovitrum AB (publ) (BIOVF) Stock Price, News & Analysis

About Swedish Orphan Biovitrum AB (publ) Stock (OTCMKTS:BIOVF)

BIOVF Stock Price History

BIOVF Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

BIOVF Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info